HH
Therapeutic Areas
Sutro Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Luveltamab tazevibulin (STRO-002) | Folate receptor-alpha (FolRα) expressing ovarian cancer | Phase 2/3 |
| STRO-003 | ROR1-expressing solid tumors | Preclinical |
| Next-generation ADCs | Undisclosed cancers | Discovery/Preclinical |
| Cytokine-based Immuno-oncology | Undisclosed cancers | Research |
Leadership Team at Sutro Biopharma
JC
Jane Chung
Chief Executive Officer & Member, Board of Directors
DP
David Pauling
Chief Administrative Officer and General Counsel
GC
Greg Chow
Chief Financial Officer
HG
Hans-Peter Gerber
Chief Scientific Officer
DL
Devendra Luhar
Senior Vice President, Technical Operations
KL
Kari Leetch
Senior Vice President, Head of People and Culture
CM
Connie Matsui
Chair, Board of Directors
JP
James Panek
Member, Board of Directors
SJ
Sukhi Jagpal
Member, Board of Directors
DH
Daniel H. Petree
Member, Board of Directors